A new study published in the Journal of American Medical Association showed that Ethosuximide was linked to decreased ...

Ethosuximide does not demonstrate efficacy over placebo for the treatment of irritable bowel syndrome-related abdominal pain and has limited tolerability.

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first approved drug. The company received notice from the U.S. Food and Drug ...

ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire ...

In patients with hypertension, starting therapy with an angiotensin receptor blocker (ARB) is associated with the best ...

HAVE you set any New Year’s resolutions? January is full of promises to “start again”, which may fill you with hope or dread.

"The main side effect is them not working! Not everyone responds to every drug." The common blood pressure drug you may want ...